Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jennifer Robinson Diamond"'
Autor:
Jennifer Robinson Diamond, Jason Timothy Henry, Gerald Steven Falchook, Anthony J. Olszanski, Harshabad Singh, E. Jane Leonard, Richard C. Gregory, Vicky A. Appleman, John Gibbs, Carole Harbison, Cong Li, Jessica M. Sapiro, Tomoki Yoneyama, Alexander A Parent, Vincent Chung
Publikováno v:
Journal of Clinical Oncology. 40:TPS2690-TPS2690
TPS2690 Background: Tumor resistance to immune checkpoint inhibitors (CPIs), including pembrolizumab, is common. Suggested mechanisms of resistance include reduced interferon (IFN) signaling, immune escape, and immunosuppressive tumor phenotypes. Inn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19e3eb09d19b2147316f4053b7a0e1ed
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2690
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2690
Autor:
S. Lindsey Davis, Alexis Diane Leal, Wells A. Messersmith, Christopher Hanyoung Lieu, Elaine T. Lam, Bradley Corr, Cindy L. O'Bryant, Natalie Julie Serkova, Todd Pitts, Jennifer Robinson Diamond
Publikováno v:
Journal of Clinical Oncology. 40:3112-3112
3112 Background: In prior work, senescence and up-regulation of genes in the PI3K/AKT/mTor pathway were observed in patient-derived xenograft models treated with alisertib to resistance, and tumor growth inhibition was observed when MLN0128 (sapanise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8488a139a7e9cbc6d318390cc5b1c1c8
https://doi.org/10.1200/jco.2022.40.16_suppl.3112
https://doi.org/10.1200/jco.2022.40.16_suppl.3112